Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

BACKGROUND: Incretin-based therapies including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) receptor agonists are novel medications for type 2 diabetes management. Several studies have found cardioprotective effects of incretin-based therapies; however, it remains un...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawwas, Ghadeer K., Smith, Steven M., Park, Haesuk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048850/
https://www.ncbi.nlm.nih.gov/pubmed/30016946
http://dx.doi.org/10.1186/s12933-018-0746-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048850/
https://www.ncbi.nlm.nih.gov/pubmed/30016946
http://dx.doi.org/10.1186/s12933-018-0746-4

Ejemplares similares